These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10459402)

  • 21. Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients?
    Kertzman S; Vainder M; Reznik I; Gotzlav Y; Weizman A; Kotler M; Iancu I
    Int Clin Psychopharmacol; 2012 May; 27(3):134-41. PubMed ID: 22415223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients.
    Lotrich FE; Pollock BG; Kirshner M; Ferrell RF; Reynolds Iii CF
    J Psychiatry Neurosci; 2008 Mar; 33(2):123-30. PubMed ID: 18330458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of lamotrigine on platelet serotonin concentration in patients with bipolar depression.
    Sagud M; Pivac N; Mustapic M; Nedic G; Peles AM; Kramaric M; Jakovljevic M; Muck-Seler D
    Psychopharmacology (Berl); 2008 May; 197(4):683-5. PubMed ID: 18246328
    [No Abstract]   [Full Text] [Related]  

  • 24. Effectiveness of mirtazapine as add-on to paroxetine
    Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
    Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea.
    Pae CU; Bahk WM; Jon DI; Lee SY; Yoon BH; Min KJ
    Hum Psychopharmacol; 2007 Aug; 22(6):351-9. PubMed ID: 17487934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet counts in depressed patients treated with amitriptyline or paroxetine.
    Lederbogen F; Hörer E; Hellweg R; Heuser I; Deuschle M
    Eur Psychiatry; 2003 Mar; 18(2):89-91. PubMed ID: 12711406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma serotonin level after 1 day of fluoxetine treatment: a biological predictor for antidepressant response?
    Alvarez JC; Gluck N; Fallet A; Grégoire A; Chevalier JF; Advenier C; Spreux-Varoquaux O
    Psychopharmacology (Berl); 1999 Mar; 143(1):97-101. PubMed ID: 10227085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting.
    Benedetti F; Colombo C; Pirovano A; Marino E; Smeraldi E
    Psychopharmacology (Berl); 2009 Mar; 203(1):155-60. PubMed ID: 18989660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sexual function during bupropion or paroxetine treatment of major depressive disorder.
    Kennedy SH; Fulton KA; Bagby RM; Greene AL; Cohen NL; Rafi-Tari S
    Can J Psychiatry; 2006 Mar; 51(4):234-42. PubMed ID: 16629348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonin transporter polymorphism and bleeding time during SSRI therapy.
    Hougardy DM; Egberts TC; van der Graaf F; Brenninkmeijer VJ; Derijks LJ
    Br J Clin Pharmacol; 2008 May; 65(5):761-6. PubMed ID: 18279474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism.
    Abdelmalik N; Ruhé HG; Barwari K; van den Dool EJ; Meijers JC; Middeldorp S; Büller HR; Schene AH; Kamphuisen PW
    J Thromb Haemost; 2008 Dec; 6(12):2168-74. PubMed ID: 18983505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin.
    Narayan M; Anderson G; Cellar J; Mallison RT; Price LH; Nelson JC
    J Clin Psychopharmacol; 1998 Feb; 18(1):67-71. PubMed ID: 9472845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dose-escalation of SSRIS in major depressive disorder. Should not be recommended in current guidelines].
    Ruhé HG; Booij J; van Weert HC; Reitsma JB; Franssen EJ; Michel MC; Schene A
    Tijdschr Psychiatr; 2010; 52(9):615-25. PubMed ID: 20862644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of tolerance of venlafaxine, paroxetine and amitriptyline in depression therapy.
    Miskovic M
    Med Arch; 2015 Apr; 69(2):107-9. PubMed ID: 26005260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
    Cusin C; Serretti A; Zanardi R; Lattuada E; Rossini D; Lilli R; Lorenzi C; Smeraldi E
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):27-35. PubMed ID: 12057029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do venlafaxine XR and paroxetine equally influence negative and positive affect?
    Dichter GS; Tomarken AJ; Freid CM; Addington S; Shelton RC
    J Affect Disord; 2005 Apr; 85(3):333-9. PubMed ID: 15780704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term sertraline treatment and peripheral biochemical markers in female depressed patients.
    Pivac N; Mück-Seler D; Sagud M; Jakovljević M; Mustapić M; Mihaljević-Peles A
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):759-65. PubMed ID: 12921906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine.
    Owens MJ; Krulewicz S; Simon JS; Sheehan DV; Thase ME; Carpenter DJ; Plott SJ; Nemeroff CB
    Neuropsychopharmacology; 2008 Dec; 33(13):3201-12. PubMed ID: 18418363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.